Medical School or Training
University of Michigan Medical School, 2001
University of Chicago Medical Center, Pediatrics, IL, 2005
Pediatric Nephrology, University of Michigan Health System, 2008
Dr. Blatt has research interests in both acute kidney injury and in the impact of renal failure on immune function. He studies novel urinary biomarkers to help diagnose acute kidney injury, and the impact of both chronic renal failure and renal replacement therapy (dialysis) on lymphocyte and monocyte function. He has been involved in the development of Bz-423, a novel lead compound for the treatment of autoimmune disease.
Dr. Neal Blatt received his bachelor's degree in Linguistics from the University of Michigan in 1992. Upon completion of his undergraduate training, he enrolled in the University of Michigan's Medical Scientist Training (MD-PhD) Program. During his doctoral studies, Dr. Blatt first developed his interest in Nephrology as a result of his research on Bz-423, a novel benzodiazepine that treats lupus nephritis in mouse models of the disease. After completion of his MD and PhD degrees, Dr. Blatt pursued a residency in General Pediatrics at the University of Chicago, and then returned to the University of Michigan in 2005 for his fellowship training in Pediatric Nephrology. Dr. Blatt joined the faculty at Michigan in 2008.
In addition to providing both general inpatient and outpatient nephrology care, Dr. Blatt is the Nephrology lead of the Interdisciplinary Systemic Inflammation clinic, which, in collaboration with Pediatric Rheumatology, provides comprehensive coordinated care for children with diseases such as Systemic Lupus Erythematosus and Systemic Vasculitis that affects the kidneys and multiple tissues and organs throughout the body.
Dr. Blatt is a fellow in the American Academy of Pediatrics, the American Society of Nephrology, the American Society of Pediatric Nephrology, and in 2010 became a member of the Society for Pediatric Research.